Comparison

Cagrilintide vs. Petrelintide

Two peptides side-by-side — identity, evidence base, legal status and known adverse events.

Identity

Mechanism of action

Cagrilintide

Cagrilintide binds amylin receptors (AMY1, AMY3, formed by the calcitonin receptor plus RAMP proteins). Activation delays gastric emptying, inhibits postprandial glucagon secretion and modulates central satiety signalling via area postrema neurons. An acyl modification enables albumin binding and thereby weekly dosing.

Petrelintide

As an amylin analogue, petrelintide acts through amylin receptors, promoting satiety and slowed gastric emptying — a satiety pathway independent of the GLP-1 axis.

Evidence base

Highest evidence

Human RCT

Studies

of which in humans

Effects recorded

Open conflicts

Documented adverse events

Legal status

Country	Cagrilintide	Petrelintide
Germany	Unapproved	Unapproved
DK	Unapproved	—
United States	Unapproved	Unapproved

Full entries

Frequently asked questions

What is the difference between Cagrilintide and Petrelintide?: Cagrilintide is classified as "Metabolic", while Petrelintide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Cagrilintide or Petrelintide?: The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Cagrilintide and Petrelintide in Germany and the United States?: Germany: Cagrilintide — Unapproved, Petrelintide — Unapproved. United States: Cagrilintide — Unapproved, Petrelintide — Unapproved. These are factual summaries with source and review date on the individual pages.

Country

Cagrilintide

Petrelintide

Germany

Unapproved

—

United States

Unapproved

Frequently asked questions

What is the difference between Cagrilintide and Petrelintide?

Cagrilintide is classified as "Metabolic", while Petrelintide is classified as "Metabolic". Cagrilintide: Synthetic long-acting amylin analog being developed in combination with semaglutide (CagriSema). Phase 3 trials for obesity and type 2 diabetes are ongoing. No marketing approval yet. Petrelintide: Petrelintide is a long-acting amylin analogue (Zealand Pharma, with Roche) for once-weekly subcutaneous use — developed for weight management with a focus on strong tolerability. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Cagrilintide or Petrelintide?

The highest available evidence level is "Human RCT" for Cagrilintide and "Human RCT" for Petrelintide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Cagrilintide and Petrelintide in Germany and the United States?

Germany: Cagrilintide — Unapproved, Petrelintide — Unapproved. United States: Cagrilintide — Unapproved, Petrelintide — Unapproved. These are factual summaries with source and review date on the individual pages.